TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Immuron Limited ( (AU:IMC) ).
Immuron Limited announced a change in the director’s interest, with Daniel Pollock acquiring an additional 1,000,000 unlisted options, as approved by shareholders at the company’s Annual General Meeting. This change reflects the company’s ongoing efforts to align its leadership’s interests with its strategic goals, potentially impacting its market positioning and stakeholder confidence.
More about Immuron Limited
Immuron Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of oral immunotherapeutics for the treatment of gut-mediated diseases.
Average Trading Volume: 538,302
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$17.23M
Find detailed analytics on IMC stock on TipRanks’ Stock Analysis page.